Format

Send to

Choose Destination
Nan Fang Yi Ke Da Xue Xue Bao. 2011 Mar;31(3):554-6.

[Effect of glucocorticoid treatment on the clinical outcome of patients with early-stage liver failure].

[Article in Chinese]

Author information

1
Department of Hepatology, Jiujiang Third People Hospital, Jiujiang 33200, China. 888wujinyu@163.com

Abstract

OBJECTIVE:

To assess the therapeutic effect and safety of short-term low-dose glucocorticoid in the treatment of early-stage subacute liver failure.

METHODS:

Eight-seven patients with early-stage HBV-related subacute liver failure were randomized into glucocorticoid treatment group (n=43) and control group (n=44). The patients in the control group received lamivudine and routine integrated treatment), and those in the treatment group were given additional short-term low-dose glucocorticoid treatment. The endpoint measurements included the survival rate, mean hospital stay and adverse reactions to the treatments.

RESULTS:

The patients receiving glucocorticoid treatment exhibited significantly greater improvement of the liver functions than those in the control group (P<0.05). The rate of successful treatment was significantly higher in treatment group with shortened hospital stay (P<0.05), but the virological response rate and incidence of complications showed no significant differences between the two groups (P>0.05).

CONCLUSION:

The short-term low-dose glucocorticoid treatment can improve survival rate and shorten the mean hospital stay of patients with HBV-related early-stage subacute liver failure patients. Glucocorticoid treatment is relatively safe when administered with strictly controlled indications and time window for intervention.

PMID:
21421506
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center